TIGER 1: A randomized, open-label, phase II study of CO-1686 or Erlotinib as first-line treatment of patients with EGFR-Mutant advanced non-small cell lung cancer
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
Clovis Oncology, Inc.
Start Date
August 1, 2015
End Date
May 19, 2017
Administered By
Duke Cancer Institute
Awarded By
Clovis Oncology, Inc.
Start Date
August 1, 2015
End Date
May 19, 2017